Serum Tumor Markers and Molecular Biological Diagnosis in Pancreatic Cancer
- 1 April 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Pancreas
- Vol. 28 (3) , 263-267
- https://doi.org/10.1097/00006676-200404000-00009
Abstract
Recent studies on genetic abnormalities in pancreatic ductal cancer have led to the investigation of tumor markers and genetic markers in both serum and pancreatic juice (PJ). Serum type 1 chain carbohydrate antigens such as CA19-9 are positive in nearly 80% of patients with pancreatic cancer (PCa), of which most are in advanced stage, whereas false-positive rates are relatively high at 20%–30% in benign hepatobiliary and pancreatic diseases. Although the prevalence of type 2 chain carbohydrate antigens, such as SLX, is relatively low, cancer specificity of these antigens is high. However, serum tumor markers have limited diagnostic value for early detection of PCa. In PJ collected endoscopically from patients with PCa, K-ras mutations (KRM) are detectable in > 80%, whereas KRM are observed in 20%–30% of PJ from patients with chronic pancreatitis (CP), reflecting benign mucous cell hyperplasia harboring KRM. Thus, a qualitative analysis of KRM in PJ is unsuitable for diagnosis of PCa. On the other hand, using an hybridization protection assay that can quantitatively determine KRM, KRM were positive in 66% of PCa but only in 40% of CP cases, indicating that qualitative analysis of KRM in PJ may be useful for differentiating PCa from CP. p53 Mutations are found in 4%–50% in PJ from patients with PCa but are not detectable in PJ from CP, suggesting that the specificity of p53 mutations is very high for PCa. Furthermore, p53 mutations were detected in 7 of 15 (47%) patients with PCa in which the PJ cytologic diagnosis was negative. Telomerase (TE) activity or its catalytic subunit, h-TERT, was reportedly positive >80% in PJ from PCa but was detected in <20% of PJ from CP. TE activity in PJ from CP originates from lymphocytes. The development and application of these new genetic and epigenetic markers with high specificity and sensitivity for PCa in serum and PJ will significantly improve our diagnostic accuracy.Keywords
This publication has 10 references indexed in Scilit:
- Quantitative analysis of K-ras gene mutation in pancreatic tissue obtained by endoscopic ultrasonography-guided fine needle aspiration: clinical utility for diagnosis of pancreatic tumorAmerican Journal of Gastroenterology, 2002
- Usefulness of Supernatant of Pancreatic Juice for Genetic Analysis of K-ras in Diagnosis of Pancreatic CarcinomaPancreas, 2001
- Telomerase activity in pure pancreatic juice for the diagnosis of pancreatic cancer may be complementary to K-ras mutationGastrointestinal Endoscopy, 2000
- K-ras mutations in duodenal aspirate without secretin stimulation for screening of pancreatic and biliary tract carcinomaCancer, 1999
- Diagnosis of Pancreatic Cancer by Detecting Telomerase Activity in Pancreatic Juice: Comparison With K- Ras MutationsAmerican Journal of Gastroenterology, 1999
- Detection of K-ras and p53 Gene Mutations in Pancreatic Juice for the Diagnosis of Intraductal Papillary Mucinous TumorsPancreas, 1999
- Quantitative Determination of K-ras Mutations in Pancreatic Juice for Diagnosis of Pancreatic Cancer Using Hybridization Protection AssayPancreas, 1998
- The establishment of a preoperative diagnosis of pancreatic carcinoma using cell specimens from pancreatic duct brushing with special attention to p53 mutationsCancer, 1998
- Telomerase Activity for the Preoperative Diagnosis of Pancreatic CancerJNCI Journal of the National Cancer Institute, 1997
- Detection of K‐ras Point Mutations at Codon 12 in Pancreatic Juice for the Diagnosis of Pancreatic Cancer by Hybridization Protection Assay: A Simple Method for the Determination of the Types of Point MutationsJapanese Journal of Cancer Research, 1996